Clinical Trial Update: Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an adaptive Phase 1/2 study evaluating dual-target CAR-NK cells in relapsed/refractory small cell lung cancer and indicates…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Dual-Target CAR-NK Cells

Snippet

Sponsor: Beijing Biotech | Conditions: Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC | Phase 1, Phase 2 | Status: RECRUITING